Showing 2111-2120 of 5909 results for "".
- FDA Approves CooperVision Biofinity Toric Multifocal Contact Lenseshttps://modernod.com/news/fda-approves-coopervision-biofinity-toric-multifocal-contact-lenses/2477277/The FDA has granted CooperVision approval for its new Biofinity toric multifocal contact lenses. The product combines the optical designs of CooperVision’s Biofinity toric—the most prescribed toric lens on the market1—and Biofinity multifocal to provide patients with astigmatism and pr
- Trefoil Therapeutics Selects AGC Biologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseaseshttps://modernod.com/news/trefoil-therapeutics-selects-agc-biologics-as-lead-manufacturer-of-tthx1114-for-treatment-of-corneal-diseases/2477274/AGC Biologics, a global Contract Development and Manufacturing Organization for Biopharmaceuticals, and Trefoil Therapeutics announce the execution of a manufacturing contract to supply their lead compound, TTHX1114. Trefoil is developing products based on this engineered form of FGF-1 to restore
- Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairshttps://modernod.com/news/aerie-pharmaceuticals-announces-appointment-of-michelle-senchyna-phd-as-vice-president-clinical-development-and-medical-affairs/2477271/Aerie Pharmaceuticals announced the appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairs, reporting to David A. Hollander, MD, MBA, Aerie’s Chief Research & Development Officer. Dr. Senchyna will lead and direct the clinical development and
- AOA Receives Department of Justice Approval to Expand Group Purchasing Activities for Its AOAExcel Membershttps://modernod.com/news/aoa-receives-department-of-justice-approval-to-expand-group-purchasing-activities-for-its-aoaexcel-members/2477244/The Department of Justice (DOJ) announced January 15 that it will not challenge a proposal by the American Optometric Association to expand its group purchasing organization’s (GPO) activities to include the purchase of optometric products for resale to consumers, specifically eyeglass lenses, fr
- FDA Accepting Less Data, More Surrogate Endpoints in Trialshttps://modernod.com/news/fda-accepting-less-data-more-surrogate-endpoints-in-trials/2477241/Over the last four decades, the FDA has loosened its requirements for approving new drugs, increasingly accepting less data and more surrogate endpoints in clinical trials, and shortening its reviews, according to a new analysis, as reported</
- Analysis: FDA’s Efforts to Speed Drug Approval May Have Led to Less Rigorous Clinical Outcome Requirementshttps://modernod.com/news/analysis-fdas-efforts-to-speed-drug-approval-may-have-led-to-less-rigorous-clinical-outcome-requirements/2477231/An analysis published in JAMA suggests that efforts by the FDA to speed the development and approval of drugs may have led to a reduction in the amount of evidence available at the time of authorization by the agency and an increase in more surrogate measures. However, the authors noted
- AbbVie Announces Leadership Team and Creation of New Business, Allergan Aesthetics, Upon Completion of Acquisitionhttps://modernod.com/news/abbvie-announces-leadership-team-and-creation-of-new-business-allergan-aesthetics-upon-completion-of-acquisition/2477216/AbbVie announced the creation of a new global business, Allergan Aesthetics, and the proposed leadership team for the combined company, effective upon the expected first-quarter 2020 close of the Allergan acquisition. Allergan Aesthetics will operate as a new global dedicated business wit
- Tarsus Pharmaceuticals Raises $60 Million for Demodex Blepharitis Drug Trialhttps://modernod.com/news/tarsus-pharmaceuticals-raises-60-million-for-demodex-blepharitis-drug-trial/2477213/Tarsus Pharmaceuticals announced the completion of $60 million in Series B financing. Tarsus will use the funds to initiate a phase 2b/3 trial in the United States of their lead product TP-03 for Demodex blepharitis and fuel phase 1 and 2 development of other clinical programs. An estimate
- AI Diagnostics Company IDx Announces New Appointments to its Executive Leadership Teamhttps://modernod.com/news/ai-diagnostics-company-idx-announces-new-appointments-to-its-executive-leadership-team/2477153/IDx Technologies announced several new appointments to its executive leadership team to accelerate product development and scale operations to accommodate increased market adoption of IDx-DR, according to a company news release. IDx-DR is an FDA-authorized autonomous AI system that detects diabet
- EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Developmenthttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-george-o-elston-as-chief-financial-officer-and-head-of-corporate-development/2477091/EyePoint Pharmaceuticals announced the appointment of George O. Elston as Chief Financial Officer and Head of Corporate Development. Mr. Elston has previously been a consultant to the company and will now transition into this permanent role effective immediately. In this role, Mr. Elston will lea